Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2017 / Articles / Aug / Advancing Medicine
Manufacture Advanced Medicine Technology and Equipment Bioprocessing - Single Use Systems Facilities & Equipment Technology & Manufacturing Bioprocessing Biopharma

Advancing Medicine

Can cell and gene therapies paint a picture of perfect future health?

By Stephanie Vine 08/09/2017 1 min read

Share

This special PDF supplement focuses on one of the most exciting fields of medicine that has emerged in recent years – advanced therapies. According to the EMA, advanced therapy medicinal products are medicines based on genes or cells that offer “groundbreaking new opportunities for the treatment of disease and injury”. A handful of cell and gene therapy products have already been approved by US or EU regulators – and more are set to follow. Cell and gene therapies are still a very long way from the hype of complete cures and revolutionary treatment options, but many are encouraged by the speed at which the field is progressing. We know that cell therapies can have clinical effects; the questions now are what conditions can benefit? How do we maximize efficacy and safety? And how do we scale up manufacture to reach larger patient numbers? In this supplement, gurus from across the field discuss the progress that advanced medicines are making, and how the industry is approaching the complex challenges posed by the supply chain and commercial manufacture.

List of articles

Hype to Hope
A handful of cell- and gene-based therapies have now been approved, and more are sure to follow.
Putting a Stop to Cell Therapy “Snake Oil”
We need to stop companies from using loopholes to sell unproven cell therapies to desperate patients.
Conducting the Supply Chain Orchestra
To effectively develop advanced therapies, you need the right supply chain management.
Being Seen and Heard
In the growing field of advanced therapies, it's important to stick out from the crowd.
What About Gene Therapies?
As fast as gene therapies are progessing, there's still one major hurdle to overcome: cost.
Gurus of Advanced Medicine
Five gurus discuss the exciting developments in advanced medicine, and what the field needs to move forward.
The Big (Bio) Freeze
When it comes to cryopreserving cell therapies, there's a right way - and a wrong way…
Banking on Cell Therapy
Sitting down with Steve Oh from the Stem Cell Bioprocessing, Bioprocessing Technology Institute, A*STAR

Download the eBook here

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.